Clinical Context
Asthma is a chronic inflammatory disease of the airways characterized by wheezing, coughing, shortness of breath, and chest tightness. It affects an estimated 363 million people worldwide, leading to significant morbidity and mortality, particularly in low- and middle-income countries where under-diagnosis and under-treatment are prevalent [1]. Current treatment strategies often involve inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), but many patients still experience uncontrolled symptoms. This highlights a gap in effective management for those with severe asthma. Triple inhaler therapy, which combines ICS, LABA, and long-acting muscarinic antagonist (LAMA), is being evaluated for its efficacy in reducing exacerbations and improving overall asthma control.
Key Findings
- The recent guidelines emphasize that the selection of patients for triple inhaler therapy should be based on their asthma severity, frequency of exacerbations, and response to previous treatments.
- Patients with uncontrolled asthma despite the use of medium-dose ICS plus LABA are eligible for step-up to triple therapy with Trimbow, Trelegy, or Breztri.
- The primary endpoint for evaluating the efficacy of these therapies is the reduction in exacerbation rates.
- Event rates indicate that patients on triple therapy experience fewer exacerbations compared to those on dual therapy.
- The primary endpoint is defined as the annualized rate of severe asthma exacerbations requiring hospitalization or emergency care.
- Dosing information for these inhalers varies, and clinicians should refer to the prescribing information for specific guidance.
Safety & Tolerability
- Common adverse events associated with triple inhaler therapy include oral candidiasis, pneumonia, and upper respiratory tract infections.
- Hyperglycemia reported with these inhalers — exact frequency not available in public source summary [1].
- Dizziness reported — exact frequency not available in public source summary [1].
- Patients should be monitored for potential cardiovascular effects, including increased heart rate and blood pressure [1].
- Discontinuation rates due to adverse events are not available in public source summary.
- Complete adverse event profile available in the full prescribing information for Trimbow, Trelegy, and Breztri.
Study Design
The guidelines for asthma management were based on a comprehensive review of clinical trials evaluating the efficacy of triple inhaler therapy in patients with severe asthma. These studies included diverse populations and assessed various endpoints, including exacerbation rates and quality of life metrics. Limitations of the studies include variability in patient adherence and differences in inhaler technique, which may affect outcomes. Further research is needed to explore long-term safety and efficacy in different patient demographics.
FAQ
What is Trimbow approved for?
Trimbow is approved for the maintenance treatment of patients with severe asthma. It combines a corticosteroid, a long-acting beta-agonist, and a long-acting muscarinic antagonist to improve lung function and control symptoms.
How does Trimbow work?
Trimbow works by reducing inflammation in the airways, relaxing the muscles around the airways, and preventing bronchoconstriction, thus improving airflow and reducing asthma symptoms.
What is the recommended dose of Trimbow?
Full dosing guidance is available in the prescribing information for Trimbow.
What are the most common side effects of Trimbow?
Common side effects include oral candidiasis, pneumonia, and upper respiratory tract infections. Patients should be monitored for these adverse events during treatment.